Get the Stockscreener App
0.3705
12.33%
-0.0521
Pre-market:
.37
-0.0005
-0.13%
Scisparc Ltd stock is traded at $0.3705, with a volume of 590.74K.
It is down -12.33% in the last 24 hours and down -35.81% over the past month.
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$0.4226
Open:
$0.4109
24h Volume:
590.74K
Relative Volume:
0.07
Market Cap:
$4.01M
Revenue:
$1.75M
Net Income/Loss:
$-5.68M
P/E Ratio:
-0.076
EPS:
-4.8726
Net Cash Flow:
-
1W Performance:
-24.92%
1M Performance:
-35.81%
6M Performance:
+0.95%
1Y Performance:
-90.22%
1-Day Range:
$0.357
$0.4155
1-Week Range:
$0.357
$0.4915
52-Week Range:
$0.197
$4.2861
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
0.3705 | 4.01M | 1.75M | -5.68M | 0 | -4.8726 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc Ltd. Reaches Favorable Lawsuit Settlement, Secures Cash Compensation and IP Rights - TipRanks
How Are Things Looking For SciSparc Ltd (NASDAQ: SPRC) For The Short Term? - Stocks Register
SciSparc Reveals Favorable Cash Settlement In Lawsuit, Shares Up - Nasdaq
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology - The Manila Times
SciSparc Ltd. Secures Settlement Agreement in Lawsuit Against Former Directors, Retaining Key Intellectual Property Rights - Nasdaq
SciSparc Secures Favorable Settlement in Lawsuit It Filed, - GlobeNewswire
Legal Victory: SciSparc Claims $411K Settlement and Complete IP Control in Strategic Court Win - StockTitan
SPRC’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
SciSparc Ltd (SPRC) Shares Soar Above 1-Year High - The News Heater
Views of Wall Street’s Leading Experts on SciSparc Ltd - SETE News
Behind SciSparc Ltd’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - GlobeNewswire
SciSparc and Clearmind’s Patent Publication Marks Progress in Binge Behavior Treatment - TipRanks
SciSparc Ltd.-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - Marketscreener.com
SciSparc Ltd. and Clearmind Medicine Inc. Collaborate on Patent Application for Innovative Combination Therapy to Address Binge Behaviors - Nasdaq
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico - The Manila Times
Game-Changing Addiction Treatment Patent: SciSparc-Clearmind's MDMA Breakthrough Expands Global Reach - StockTitan
SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN
Jeffs' Brands Negotiates $11.8M Sale of Smart Repair Pro to Canadian Company in Major Restructuring - StockTitan
Minerva Neurosciences (NASDAQ:NERV) vs. SciSparc (NASDAQ:SPRC) Financial Contrast - Defense World
SciSparc gets Nasdaq extension to regain compliance - MSN
SciSparc (NASDAQ:SPRC) Stock Quotes, Forecast and News Summary - Benzinga
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - GlobeNewswire
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing - Marketscreener.com
SciSparc, Automax enters direct import market with $13M first shipment of JAC EVs - MSN
SPRCSciSparc Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
SciSparc Granted Nasdaq Compliance Extension - TipRanks
SciSparc Secures Critical Nasdaq Extension to Meet $1 Minimum Bid Requirement - StockTitan
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles - GlobeNewswire
SciSparc's AutoMax Secures First $13M JAC Motors EV Shipment for Israeli Market Launch - StockTitan
SciSparc says MitoCareX expands research to pancreatic cancer - Yahoo Finance
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Scisparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results - GlobeNewswire
SciSparc's MitoCareX Breakthrough: AI-Powered Platform Shows Promise in Pancreatic Cancer Treatment - StockTitan
SciSparc and Clearmind Medicine Advance with European Patent Application for Psychedelic Binge Behavior Treatment - TipRanks
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet - Benzinga
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? - AOL
Stock market today: AEON Biopharma saw gain of 255.62% while SciSparc increased by 89.77% in early trading - Business Upturn
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc and Clearmind Secure European Patent for Groundbreaking Binge Behavior Treatment - StockTitan
Pharma Stock SciSparc Ltd. (Nasdaq: SPRC) Soars on Psychedelic News - Investorideas.com newswire
IMCA renews SciSparc’s autism spectrum disorder therapy trial approval - Yahoo Finance
SciSparc Secures Approval Renewal for Autism Treatment Trial - TipRanks
SciSparc announces renewal of approval by Israeli Medical Cannabis Agency - TipRanks
SciSparc Announces Renewal of Approval by Israeli Medical - GlobeNewswire
SciSparc Advances Autism Treatment Trial: CBD-Based SCI-210 Gets Key Israeli Approval for Children's Study - StockTitan
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
SciSparc: AutoMax announces $13M first delivery of JAC vehicles - Yahoo Finance
SciSparc Supports AutoMax’s $13 Million JAC Motors Vehicle Import - TipRanks
S&P 500 Edges Lower, SciSparc Shares SurgeSEALSQ (NASDAQ:LAES), Baosheng Media Gr (NASDAQ:BAOS) - Benzinga
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):